ChromaDex Launches Niagen® IV for Enhanced Cellular Health Nationwide
- ChromaDex launches Niagen® IV, a pharmaceutical-grade NAD+ precursor, now available at over 200 Restore Hyper Wellness locations.
- Niagen IV enhances NAD+ levels by 20% post-infusion, requiring 75% less time than traditional therapies.
- ChromaDex emphasizes consumer education about NAD+ supplements, promoting informed health and wellness choices.
ChromaDex Expands Availability of Niagen® IV to Enhance Cellular Health
ChromaDex Corp., a frontrunner in nicotinamide adenine dinucleotide (NAD+) research, announces the nationwide rollout of its pharmaceutical-grade nicotinamide riboside chloride (NRC) product, Niagen® IV. This innovative intravenous therapy is now accessible at over 200 Restore Hyper Wellness locations across the United States, marking a significant step forward in the field of NAD+ treatment. Niagen IV aims to support cellular health and extend healthspan, catering to wellness enthusiasts seeking scientifically validated options to improve their overall well-being.
The introduction of Niagen IV is pivotal, as it represents the most efficient NAD+ precursor available, crucial for various metabolic processes and energy production within cells, which tend to decline with age and lifestyle stressors. Clinical studies demonstrate that Niagen IV significantly enhances whole blood NAD+ levels, achieving a 20% increase three hours post-infusion while requiring 75% less infusion time compared to traditional NAD+ intravenous therapies. This advancement not only positions ChromaDex as a leader in the NAD+ market but also underscores the company’s commitment to delivering cutting-edge solutions that promote optimal health.
Rob Fried, CEO of ChromaDex, highlights the profound benefits of Niagen IV, which aligns with the growing trend toward proactive health management through evidence-based interventions. Dr. Rachele Pojednic from Restore Hyper Wellness emphasizes the importance of integrating safety and efficacy into wellness experiences, reinforcing the value of Niagen IV within their clinical offerings. Compounded and distributed by Wells Pharma, a U.S. FDA-registered facility, Niagen IV is designed for medical use, ensuring that clients receive a safe and effective treatment tailored to their needs.
In addition to the rollout of Niagen IV, ChromaDex continues to focus on consumer education regarding the benefits of NAD+ supplements. The company encourages potential users to visit Restore's website or sign up for updates on the Niagen Plus site for further information. This initiative reflects ChromaDex's dedication to fostering informed choices in health and wellness, further solidifying its position within the industry.
As the health and wellness landscape evolves, the introduction of Niagen IV signifies a growing recognition of the importance of cellular health. ChromaDex’s efforts not only contribute to advancing therapeutic options but also resonate with a demographic increasingly interested in scientifically supported methods to enhance their vitality and longevity.